title: Effects of non-steroidal anti-inflammatory drugs on prostacyclin and thromboxane biosynthesis in patients with mild essential hypertension.
abstract: 1. The effects of non-steroidal anti-inflammatory drugs (NSAID) on prostacyclin and thromboxane biosynthesis and on blood pressure were determined in 46 patients with mild essential hypertension. Patients who had abstained from antihypertensive therapy for 2 weeks before study were treated with either aspirin, ibuprofen, sulindac or placebo for 7 days. 2. Excretion rates of 2,3-dinor-6-oxo-prostaglandin (PG) F1 alpha, 6-oxo-PGF1 alpha, 2,3-dinorthromboxane (TX) B2 and TXB2 were measured as indices of prostacyclin and TXA2 biosynthesis. Samples were assayed using immunoaffinity chromatography and gas chromatography/electron capture chemical ionisation mass spectrometry. 3. Aspirin and ibuprofen reduced urinary excretion of all prostacyclin- and thromboxane-derived products. Sulindac inhibited excretion of 2,3-dinor-6-oxo-PGF1 alpha, 6-oxo-PGF1 alpha and 2,3-dinor-TXB2, but had no significant effect on TXB2. 4. Systolic blood pressure increased in the ibuprofen-treated group when compared with the placebo group. There were no other significant changes in systolic or diastolic pressure in any of the treatment groups. Among the patients as a whole, there was a significant negative correlation between change in blood pressure and change in excretion of the prostacyclin-derived but not of the thromboxane-derived products. 5. We conclude that, in patients with mild essential hypertension, neither sulindac nor aspirin (in the doses used) selectively spares prostacyclin biosynthesis by the kidney. The significant relationship between increase in blood pressure and reduction in prostacyclin biosynthesis favours the possibility that in individuals who become hypertensive, prostacyclin biosynthesis determines, in part, the severity of the hypertensive state.
authors.affiliation: Department of Clinical Pharmacology, Royal Postgraduate Medical School, Hammersmith Hospital, London.
authors.forename: P
authors.initials: P
authors.lastname: Minuz
authors.forename: S E
authors.initials: SE
authors.lastname: Barrow
authors.forename: J R
authors.initials: JR
authors.lastname: Cockcroft
authors.forename: J M
authors.initials: JM
authors.lastname: Ritter
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002846:Chromatography, Affinity; D011464:Epoprostenol / Q000096:biosynthesis* / Q000097:blood; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D006973:Hypertension / Q000378:metabolism* / Q000503:physiopathology; D007052:Ibuprofen / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D013467:Sulindac / Q000494:pharmacology; D013931:Thromboxanes / Q000096:biosynthesis* / Q000097:blood
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013931:Thromboxanes; D013467:Sulindac; D011464:Epoprostenol; D001241:Aspirin; D007052:Ibuprofen